Best Neurology Companies in Canada
The 148 best Neurology companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ProMIS Neurosciences.
Canada's Neurology sector has real money behind it. This directory ranks 148 tracked companies by disclosed equity funding and recent momentum, with a collective $1.5B raised across the field. ProMIS Neurosciences leads at $247M, followed closely by Cybin at $230M, and those two alone account for a third of the total pool. No unicorns yet, but the concentration at the top tells you where conviction is sitting. The global neurology market sits at roughly $112.5B in 2025, forecast to reach $180.2B by 2032 at a 6.9% CAGR, driven by an aging population and accelerating neuroimaging research. Canada's positioned to capture a real slice of that.
What I find interesting is where the heat is moving. Coverage may be flat, but the thematic action is loud: cognitive aging, post-concussion syndrome, and chronic traumatic encephalopathy are all pulling serious research attention right now. Stress-induced neuroinflammation is another thread gaining traction in clinical circles, and epilepsy care advocacy keeps spotlighting gaps that Canadian companies are actively building toward. Investors like Ontario Brain Institute and BDC are anchoring early-stage bets. So if you're scanning for where neuroscience capital in Canada is actually moving, this is your current map.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | ProMIS Neurosciences Antibody therapeutics and diagnostics for neurodegenerative diseases 37Funding top 10%Patents top 38%Moat top 38%Talent top 38% All 9 signals ▾Fundingtop 10% Patentstop 38% Moattop 38% Talenttop 38% Newstop 42% Innovationtop 47% Globalbottom 48% Techbottom 34% Marketbottom 24% Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $247M | 4 mo ago | 7 | Neil Cashman Co-Founder | — | 78 patents Therapeutic antibodies targeting misfolded neurodegenerative proteins (TDP-43, α‑synuclein, Aβ, SOD1). | — |
| 2 | Cybin Provider of psychedelic therapeutics for psychiatric disorders 55Funding top 15%Tech top 42%Talent top 45%Moat top 48% All 6 signals ▾Fundingtop 15% Techtop 42% Talenttop 45% Moattop 48% Marketbottom 47% Globalbottom 37% Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 55/100 | $230M | 11 mo ago | 50 | Aaron Bartlone COO | — | — | — |
| 3 | Neuromed Pharmaceuticals Provider of calcium channel blockers for pain treatment | $126M | 226 mo ago | — | Peter Beltran CEO | — | 103 patents Novel small‑molecule calcium channel blocker compounds for cardiovascular therapeutics | — |
| 4 | Transition Therapeutics Small molecule therapeutics for CNS and metabolic diseases. | $113M | 143 mo ago | 18 | — | — | 16 patents Peptide-based VIP therapeutics and vitamin‑B12/IMPDH inhibitor combos for metabolic, cardiac and antiviral diseases | — |
| 5 | Reunion Neuroscience Developer of therapeutics for mental health conditions | $103M | 29 mo ago | 18 | — | — | 12 patents Design of tryptamine prodrugs and benzyltryptamine derivatives for CNS drug delivery | — |
| 6 | Xenon Pharmaceuticals Developer of small molecule drugs against rare channelopathies | $86M | 237 mo ago | 19 | Simon Pimstone CEO | 4 signals ▼43% Earnings · Funding | 1,484 patents Design and synthesis of heteroaryl amine drug candidates and prodrugs for CNS therapies | 3 awards |
| 7 | Synaptive Medical Planning and imaging solutions for neurosurgery 74Patents top 20%Funding top 23%Product top 25%Moat top 26% All 11 signals ▾Patentstop 20% Fundingtop 23% Producttop 25% Moattop 26% Innovationtop 31% Growthtop 35% Talenttop 38% Techtop 41% Markettop 43% Globaltop 45% Newsbottom 21% Patents: 730 patents matched (strict assignee match) · 264 filings since 2022 vs 378 in 2017-21 Funding: Raised $76.8M across 12 rounds · 12 rounds over 12 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $77M | 11 mo ago | 200 | Cameron Piron Co-Founder | — | 730 patents Patents concentrated in health & consumer products | — |
| 8 | NeurAxon Pharma Developer of NOS inhibiting small molecules for neuropathies | $53M | 137 mo ago | 15 | — | — | — | — |
| 9 | MSI Methylation Sciences Developer of small molecule therapies for major depressive disorder (MDD) | $48M | 116 mo ago | 11 | — | — | 14 patents Enhanced SAMe nutritional formulations and gallic acid esters for folate deficiency therapy | — |
| 10 | BIONIK Provider of assistive and rehabilitation hardware and software solutions | $40M | 108 mo ago | 12 | Michal Prywata Co-Founder | — | — | — |
| 11 | Tetra Bio-Pharma Developer of natural medicinal plant-based elements for treating multiple diseases 32Funding top 26%Talent bottom 49%Market bottom 41%Tech bottom 38% All 6 signals ▾Fundingtop 26% Talentbottom 49% Marketbottom 41% Techbottom 38% Globalbottom 36% Newsbottom 24% Funding: Raised $37.9M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 32/100 | $38M | 39 mo ago | 33 | Andre Audet Co-Founder | — | — | — |
| 12 | AlphaCognition Developer of therapeutics to treat neurological disease | $26M | 20 mo ago | 4 | Michael Mcfadden CEO | 8 signals ▼33% Earnings · Leadership | — | — |
| 13 | A Better Life Pharma Developer of cannabinoid-based therapeutics for neurological disorders 24Growth top 35%Funding top 36%News top 39%Tech bottom 48% All 7 signals ▾Growthtop 35% Fundingtop 36% Newstop 39% Techbottom 48% Globalbottom 43% Talentbottom 41% Marketbottom 11% Growth: Fresh capital in last 24 mo Funding: Raised $25.7M across 14 rounds · 14 rounds over 6 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $26M | 13 mo ago | 4 | Ahmad Doroudian Founder & CEO | — | — | — |
| 14 | Cynapsus Therapeutics Developer of treatment for CNS disorders | $25M | 134 mo ago | 30 | — | — | 47 patents Sublingual film formulations for rapid apomorphine delivery in Parkinson's therapy | — |
| 15 | Fortunafix Regenerative implants and directly reprogrammed precursor cells for brain and spinal cord injury | $25M | 103 mo ago | — | Jan Ahlfors Founder & CEO | — | — | — |
| 16 | Optina Diagnostics Developer of eye-scanning devices for Alzheimer's disease | $24M | 52 mo ago | 42 | David LaPointe CEO | — | 32 patents Advanced multispectral retinal imaging and AI-driven biomarker detection for eye diagnostics | — |
| 17 | NervGen Developer of therapeutics for the treatment of nerve damage | $22M | 44 mo ago | 11 | Harold Punnett Director | — | — | — |
| 18 | Evasc Medical Endovascular repair of cerebral aneurysms | $20M | — | 23 | — | — | — | 1 launch |
| 19 | Grey Matter Neurosciences Developer of medical devices for neurological disease treatment | $14M | 16 mo ago | — | Jeffrey Coull Founder & CEO | — | — | — |
| 20 | Neurodyn Discovering and developing bioactive compounds into treatments for neurological diseases | $14M | 80 mo ago | — | Denis Kay Founder & CSO | — | 21 patents Therapeutic agents and formulations for neurodegenerative disease using progranulin and sterol glycoside toxins. | — |
| 21 | Bionxt Developer of drug formulations and delivery systems for various diseases 37News top 36%Funding top 38%Partners top 40%Patents top 46% All 11 signals ▾Newstop 36% Fundingtop 38% Partnerstop 40% Patentstop 46% Growthtop 47% Talenttop 49% Moatbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 39% Globalbottom 38% News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $13M | 15 mo ago | 25 | Hugh Rogers CEO | 9 signals ▼36% Funding · Leadership · Contracts | 7 patents Novel psilocin prodrugs and enteric drug delivery formulations for pharmaceutical applications. | 1 partnership |
| 22 | NoNO Developing pharmaceuticals for the treatment of common health disorders, including stroke, traumatic brain… | $10M | 156 mo ago | 43 | Michael Tymianski President and CEO | — | 370 patents Neuroprotective peptide therapeutics targeting ischemic injury and reperfusion damage | — |
| 23 | Regen-Bio Manufacturer of multi-target peptide for curing CNS diseases | $9M | 51 mo ago | 11 | Ringo Ye Co-Founder | — | — | — |
| 24 | Psyence Developer of psychedelic therapeutics for mental health disorders 45News top 26%Growth top 36%Funding top 40%Global top 41% All 7 signals ▾Newstop 26% Growthtop 36% Fundingtop 40% Globaltop 41% Talenttop 49% Marketbottom 43% Techbottom 36% News: 10 BI events in 12 mo (of 25 tracked, 10 types) · +25% YoY Growth: Web rank 10,000,000 → 50,000,000 YoY · 3 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $9M | 12 mo ago | — | Alan Friedman Co-Founder | 10 signals ▲25% Board · M&A · Leadership | — | — |
| 25 | Chlorion Pharma Canadian, early stage biotech developing small molecule therapeutics for neuropathic pain and epilepsy | $8M | 204 mo ago | 11 | — | — | 21 patents Sulfur‑substituted heterocyclic pyrimidine/piperidine compounds for analgesic and anti‑inflammatory drugs | — |
| 26 | Paradox Immunotherapeutics Developer of immunotherapeutics for the treatment of rare diseases | $7M | 15 mo ago | 9 | Yulong Sun Co-Founder | — | 5 patents Therapeutic monoclonal antibodies targeting conformational epitopes of lambda immunoglobulin light chains | — |
| 27 | Winterlight Labs AI-powered speech analysis technology to detect cognitive impairments | $6M | 79 mo ago | 48 | Maria Yancheva Co-Founder And Chief Technology Officer | — | 7 patents AI-driven speech analysis for detecting cognitive and neurological disorders | — |
| 28 | DAMONA Pharmaceuticals Developer of therapeutics for the treatment of cognitive dysfunctions | $6M | 44 mo ago | 6 | Etienne Sibille Founder | — | — | — |
| 29 | CanniMed Canadian Medical Marijuana company producing standardized supply under Canadian government's ACMP regulations | $5M | 112 mo ago | 4 | Brent Zettl Founder | — | — | — |
| 30 | Cyber Kinetics Technology Brain-computer interface for severely paralyzed patients | $4M | 275 mo ago | 36 | — | — | — | — |
| 31 | Tryp Therapeutics Developer of therapeutic solutions for treating neuropsychiatric disorders & pain | $4M | 31 mo ago | 11 | — | — | 23 patents Psychedelic drug formulations and therapeutic protocols for mental/neurological disorders | — |
| 32 | HDAX Developer of small molecule drugs to treat cancer and CNS disorders | $3M | 21 mo ago | 8 | Pimyupa Manaswiyoungkul Co-Founder & COO | — | — | — |
| 33 | MyndTec Developer of functional electrical stimulation therapy for upper limb paralysis 11Funding top 34%Moat top 38%Talent bottom 45%Global bottom 40% All 7 signals ▾Fundingtop 34% Moattop 38% Talentbottom 45% Globalbottom 40% Patentsbottom 38% Marketbottom 24% Innovationbottom 19% Funding: Raised $3.2M across 13 rounds · 13 rounds over 15 yrs (0.9/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 17 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $3M | 4 mo ago | 11 | Milos Popovic Co-founder and Director | — | 17 patents Implantable neurostimulation devices with wireless telemetry for functional electrical therapy | — |
| 34 | Clairvoyant Therapeutics Manufacturer of psychedelic therapy drug for addiction | $2M | 54 mo ago | 11 | — | — | — | — |
| 35 | Rapid Dose Therapeutics Developer of drug delivery technologies to treat the elderly, pediatrics, and neurological disorders | $2M | 25 mo ago | 14 | Mark Upsdell CEO | 4 signals ▲300% Funding · Announcements | 12 patents Patents concentrated in chemistry & materials | — |
| 36 | Mynd Manufacturer of drugs for neurological disorders | $2M | 54 mo ago | — | Wilfred Jefferies Co-Founder & Chief Science Officer | — | — | — |
| 37 | Aequus Pharma Developer of pharmaceutical products for the treatment of neurology and psychiatric diseases | $2M | 70 mo ago | 18 | — | — | — | — |
| 38 | ImStar Therapeutics Small molecule therapeutics for Amyotrophic Lateral Sclerosis (ALS) and neurodegenerative diseases | $2M | 120 mo ago | 4 | Daniel Wattier Founder & CEO | — | 17 patents Therapeutic withanolide compounds targeting neurodegenerative disease treatment | — |
| 39 | Trexo Robotics A battery operated exoskeleton device | $2M | 87 mo ago | 29 | — | — | 10 patents Powered lower‑limb orthotic exoskeletons for weight‑bearing mobility assistance | 1 partnership |
| 40 | ClaroNav Developer of medical 3D visualization and surgical navigation solutions | $2M | 76 mo ago | 40 | Doron Dekel Co-Founder & Co-CEO | — | 35 patents Dental navigation and robotic-assisted oral surgery systems | — |
| 41 | Health Tech Connex Brain wave monitoring devices | $2M | 69 mo ago | 48 | — | — | — | — |
| 42 | KalGene Pharmaceuticals Developing therapeutics and companion diagnostics for Cancer and Alzheimer's. | $2M | 53 mo ago | 2 | — | — | — | — |
| 43 | Steadiwear Designer & manufacturer of healthcare gloves 29Growth top 35%Moat top 38%Tech top 42%Funding bottom 49% All 10 signals ▾Growthtop 35% Moattop 38% Techtop 42% Fundingbottom 49% Talentbottom 49% Productbottom 47% Innovationbottom 40% Globalbottom 39% Patentsbottom 37% Marketbottom 17% Growth: Fresh capital in last 24 mo Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $1M | 8 mo ago | 6 | Mark Elias Co-Founder & CEO | — | 8 patents Wearable tremor‑damping devices for involuntary hand motion control in medical applications | — |
| 44 | Lobe Sciences Developer of small-molecule-based therapeutic solutions for the treatment of neurological disorders 50Growth top 15%News top 25%Moat top 32%Patents top 35% All 10 signals ▾Growthtop 15% Newstop 25% Moattop 32% Patentstop 35% Innovationtop 41% Talenttop 44% Fundingtop 47% Techbottom 46% Globalbottom 33% Marketbottom 25% Growth: Fresh capital in last 24 mo News: 8 BI events in 12 mo (of 14 tracked, 3 types) · +700% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $942K | 2 mo ago | — | Tom Baird CEO | 8 signals ▲700% Earnings · Leadership · Funding | 25 patents Stable psilocin salt formulations for psychedelic drug development and therapeutic use. | — |
| 45 | IRegained Developer of therapeutic solutions for treating stroke or traumatic brain injury | $779K | 50 mo ago | 16 | Vineet Johnson Founder | — | 6 patents Indirect movement feedback systems for sensorimotor rehabilitation and therapeutic exercise devices. | 1 partnership |
| 46 | Quantum Biopharma Developer of therapies for neurodegenerative and neuropsychiatric diseases | $500K | 7 mo ago | — | Anthony Durkacz Co-Founder | 5 signals ▼75% Contracts · Funding · Earnings | — | 1 launch |
| 47 | Neural Therapeutics Developer of ethnobotanical drug for neurological disorder | $495K | 15 mo ago | 2 | Ian Campbell Chief Executive Officer | 3 signals ▲50% Regulatory · M&A · Announcements | — | — |
| 48 | Sairiyo Therapeutics Developer of therapeutic solutions for the treatment of rare diseases | $300K | 35 mo ago | — | Paul Slyke Co-Founder & CSO | — | — | — |
| 49 | NeuroQore Develops a monophasic repetitive transcranial magnetic stimulation (rTMS) system | $250K | 11 mo ago | 2 | — | — | — | — |
Top 12 Neurology companies in Canada
#1
Public · Toronto, Ontario · founded 2004 · 7 employees$247.3Mraised▾
ProMIS Neurosciences discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The company utilizes its computational discovery platform, ProMIS, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. It owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
- Jan 2026Post IPO$175M
- Jul 2025Post IPO$9.2M
- Sep 2023Post IPO$14.9M
- Oct 2022Post IPO$7.5M
#2
Public · Toronto, Ontario · founded 2002 · 50 employees$229.7Mraised▾
Provider of psychedelic therapeutics for psychiatric disorders. The product pipeline includes CYB003 a deuterated psilocin for the adjunctive treatment of major depressive disorderCYB004 deuterated dimethyltryptamine compound targeting generalized anxiety disorder and CYB005 aphenethylamine derivative treating neuroinflammation.
- Jun 2025Post IPO$50M
- Mar 2024Post IPO$150M
- Mar 2022Post IPO$317.1K
- Feb 2021Post IPO—
#3
Series C · Mississauga, Ontario · founded 2012 · 200 employees$76.8Mraised▾
Synaptive Medical develops planning tools and imaging solutions for application in minimally invasive neurosurgery. Its solutions include BrightMatter Prime which enables thorough and systematic pre-operative preparation with training tools, high fidelity images as well as a smooth and seamless workflow into the surgical suite; and BrightMatter™ Servo which unites high-resolution imaging capabilities with hands-free alignment while seamlessly delivering 3D tractography visualization for navigation into the surgical suite. The company acquired FDA clearance for its product BrightMatter Guide which is a 3D neuro-navigation system.
- Jul 2025Series C—
- Mar 2023Conventional Debt$40M
- Oct 2020Series C$17M
- Dec 2019Series C$25M
#4
Public · Mississauga, Ontario · founded 2008 · 11 employees$3.2Mraised▾
Developer of functional electrical stimulation therapy for upper limb paralysis. The company has developed a therapy called MyndMove based on the concepts of promoting neuroplasticity to improve the voluntary movement of the hand and arm. MyndMove can be used to treat upper extremity paralysis or paresis post-stroke, spinal cord or traumatic brain injury.
- Feb 2026Post IPO$95K
- Jan 2026Post IPO$90K
- Dec 2025Post IPO$80K
- Oct 2025Post IPO$37.5K
#5
Public · Montreal, Montreal · founded 2019 · 4 employees$25.7Mraised▾
Developer of cannabinoid-based therapeutics for neurological disorders. It has developed the commercialization of premium cannabinoid-based nutraceuticals and pharmaceutical products. Its product pipeline includes TD-0148A a non-hallucinogenic second-generation Lysergic Acid Diethylamide (“LSD”) derivative designed for the treatment of depression, post-traumatic stress disorder (“PTSD”), TD-010 for anxiety, and other neuropsychiatric disorders. and AP-003 is developed to check the therapeutic efficacy of IFNa2b in COVID-19 disease. It produces cannabinoid powder for use in capsules, stick packs, bulk powder, beverages, baked goods, and many more.
- Apr 2025Post IPO$1.1M
- Jun 2024Post IPO$175K
- May 2024Post IPO$530K
- Apr 2024Post IPO$1.2M
#6
Public · Vancouver, British Columbia · founded 2018$942.3Kraised▾
Developer of small-molecule-based therapeutic solutions for the treatment of neurological disorders. The company has developed psilocybin and N-Acetylcysteine drug for the treatment of mild traumatic brain injury & stress disorder. It has also developed devices to treat brain traumas.
- Apr 2026Post IPO$693.4K
- Jul 2025Post IPO$248.8K
- Dec 2020Post IPO—
#7
Public · Toronto, Ontario · founded 1997$8.6Mraised▾
Developer of psychedelic therapeutics for mental health disorders. The company's psilocybin drug candidates reduce the symptoms of psychological trauma, PTSD, depression, anxiety, stress, and addiction.
- Jun 2025Post IPO$441.1K
- Dec 2024Post IPO$2M
- Aug 2023Post IPO$93.5K
- Apr 2023Post IPO$2.2M
#8
Public · Vancouver, British Columbia · founded 2018 · 25 employees$12.6Mraised▾
Developer of drug formulations and delivery systems for various diseases. The company focuses on developing precision transdermal and oral dissolvable drug delivery formulations, rapid, infectious disease, and oral health screening tests, and clinical evaluation of active pharmaceutical ingredients for neurological applications. The company's product include Vektor a drug formulation for efficient and affordable delivery of approved neurological medications.
- Feb 2025Post IPO$1.7M
- Jan 2025Post IPO$138.9K
- Jan 2025Post IPO$620.1K
- Jan 2025Post IPO$288.8K
#9
Public · Vancouver, British Columbia · founded 2000 · 4 employees$25.8Mraised▾
AlphaCognition is a developer of therapeutics to treat diseases of the brain and spinal cord. The therapeutics developed are a patented new chemical entity called Alpha-1062, an acetylcholine esterase inhibitor to treat Alzheimer's disease (completed human trials). The company has also developed Alpha-602 for treating ALS.
- Sep 2024Post IPO$4.5M
- Jan 2024Post IPO$3.7M
- Dec 2023Post IPO$1.8M
- Nov 2023Post IPO$4.7M
#10
Seed · Toronto, Ontario · founded 2021$14Mraised▾
Developer of medical devices for neurological disease treatment. It offers ultrasound headset that facilitate therapeutic brain stimulation for thw treatment of Alzheimer's and other brain diseases and disorders.
- Jan 2025Seed$14M
#11
Seed · Toronto, Ontario · founded 2015 · 6 employees$1.3Mraised▾
Designer & manufacturer of healthcare gloves. The company claims that its products are designed to intelligently stabilize the wrist joint in Essential Tremor and Parkinson's disease. It allows patients to perform daily activities comfortably. Its gloves are washable and battery-free.
- Sep 2025Grant (prize money)—
- Sep 2025Seed—
- Sep 2025Conventional Debt—
- Jul 2021Seed$884.3K
#12
Series A · Toronto, Ontario · founded 2019 · 9 employees$7Mraised▾
Developer of immunotherapeutics for the treatment of rare diseases. The company has a drug design platform to develop monoclonal antibody (mAb) treatment for protein misfolding diseases. The drug pipeline inlcudes LX-96 for heart failure, KX-99 for ALECT2 amyloidosis, and NX-86 for neurodegenerative diseases.
- Feb 2025Series A$7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Canada
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,403 Canada-affiliated papers.
- University of Toronto358
- Toronto Western Hospital280
- University Health Network200
- Ontario Brain Institute94
- University of Calgary88
- Deep brain stimulation23→53
- Stimulation10→28
- Neuromodulation3→12
- Brain stimulation5→11
- Electroencephalography2→6
- Deep brain stimulation134→195
- Stimulation54→94
- Neuromodulation13→46
- Brain stimulation12→42
- Neurostimulation17→39
- Stimulation20→35
- Neuromodulation7→22
- Transcranial magnetic stimulation2→13
- Brain stimulation8→17
- Dystonia14→21
Where neurotech is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in Canada
Canada neurotech patent filing is accelerating — 67 filings from 22 assignees (2016–2025), led by EBT Medical, LIM LEW, Holland Bloorview KIDS Rehabilit; annual filings 4→10.
- EBT Medical18
- LIM LEW15
- Holland Bloorview KIDS Rehabilit11
- UNIV Health Network10
- LIM TENG LEW9
- JOHN Michael Sasha7
- Queens UNIV6
- UNIV Rennes6
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.